-
公开(公告)号：US20190023757A1
公开(公告)日：2019-01-24
申请号：US15996232
申请日：2018-06-01
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US10011642B2
公开(公告)日：2018-07-03
申请号：US15004281
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
-
3.发明授权公开(公告)号：US09493530B2
公开(公告)日：2016-11-15
申请号：US14167662
申请日：2014-01-29
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。 在一些实施方案中，FGF21突变体多肽包含位置98,171和/或180处的取代。
-
公开(公告)号：US11072640B2
公开(公告)日：2021-07-27
申请号：US15996232
申请日：2018-06-01
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
-
5.发明申请公开(公告)号：US20190085054A1
公开(公告)日：2019-03-21
申请号：US16209239
申请日：2018-12-04
Applicant: AMGEN INC.
Inventor： Jeonghoon Sun , Jason Charles O'Neill , Randal R. Ketchem , Randy Ira Hecht , Edward J. Belouski , Mark Leo Michaels
Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
-
Patent Agency Ranking
公开(公告)号：US20140243503A1
公开(公告)日：2014-08-28
申请号：US14134482
申请日：2013-12-19
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eav Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
7.发明授权公开(公告)号：US10189890B2
公开(公告)日：2019-01-29
申请号：US14775482
申请日：2014-03-13
Applicant: AMGEN INC.
Inventor： Jeonghoon Sun , Jason Charles O'Neill , Randal R. Ketchem , Randy Ira Hecht , Edward J. Belouski , Mark Leo Michaels
IPC: C07K14/435 , A61K38/16 , C12N15/09 , C12N15/11 , C12N15/12 , C12N15/63 , C07K14/81 , C12N9/64 , A61K38/00
Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
-
公开(公告)号：US20160168223A1
公开(公告)日：2016-06-16
申请号：US15004281
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
IPC: C07K14/50
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。
-
公开(公告)号：US20250136653A1
公开(公告)日：2025-05-01
申请号：US18737435
申请日：2024-06-07
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US20240076333A1
公开(公告)日：2024-03-07
申请号：US18499499
申请日：2023-11-01
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , JIng Xu
CPC classification number: C07K14/50 , A61K38/1825 , A61K2039/505
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.01 seconds)
